

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Information for the public

Published: TBC

nice.org.uk

What has NICE said?

Cabazitaxel (Jevtana), with prednisone or prednisolone, is recommended as a possible treatment for people with metastatic hormone-relapsed prostate cancer if:

- it has been treated with docetaxel
- they have an eastern cooperative oncology group performance status of 0 or 1.

Cabazitaxel should be stopped if the disease gets worse or after 10 cycles of treatment (whichever happens first).

What does this mean for me?

If you have metastatic hormone-relapsed prostate cancer, and your doctor thinks that cabazitaxel is the right treatment, you should be able to have the treatment on the NHS.

Cabazitaxel should be available on the NHS within 3 months of the guidance being issued.

Why has NICE said this?

NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.

Cabazitaxel was recommended because the benefits to patients justify its cost.

The condition and the treatments

When prostate cancer has spread to another part of the body, it is called metastatic prostate cancer. In most men with prostate cancer, the hormone testosterone makes the cancer grow faster. So prostate cancer can be treated with drugs that make the body produce less testosterone, or react to it in a different way. This is called androgen deprivation treatment.

After a time, the cancer stops responding to such treatments – this is known as 'hormone-relapsed' cancer.

The eastern cooperative oncology group (ECOG) performance status is a measure of how well you are. An ECOG status of 0 means that you are fully active, more or less as you were before your illness. A status of 1 means that you can't carry out heavy physical work, but can do anything else.

Cabazitaxel and docetaxel are anticancer drugs, used to kill cancer cells. Cabazitaxel is given by infusion into a vein. It is given with another drug called prednisone or prednisolone, which is taken as a tablet.

[NHS Choices](#) may be a good place to find out more.

Sources of advice and support

- [Cancer Research UK Patient Information](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000
- [Prostate Cancer UK](#), 0800 074 8383
- [Tackle Prostate Cancer](#), 0845 601 0766

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-1882-9

Accreditation

